| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2163 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1590 | 2018 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 569 | 2014 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 415 | 2014 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 412 | 2022 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 276 | 2014 |
| A multi-country test of brief reappraisal interventions on emotions during the COVID-19 pandemic K Wang, A Goldenberg, CA Dorison, JK Miller, A Uusberg, JS Lerner, ... Nature human behaviour 5 (8), 1089-1110, 2021 | 135 | 2021 |
| Global impact of COVID-19 on stroke care and IV thrombolysis RG Nogueira, MM Qureshi, M Abdalkader, SO Martins, H Yamagami, ... Neurology 96 (23), e2824-e2838, 2021 | 135 | 2021 |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study D Razavi-Shearer, I Gamkrelidze, C Pan, J Jia, T Berg, R Gray, YS Lim, ... The Lancet Gastroenterology & Hepatology 8 (10), 879-907, 2023 | 116 | 2023 |
| Histoplasmosis, an underdiagnosed disease affecting people living with HIV/AIDS in Brazil: results of a multicenter prospective cohort study using both classical mycology tests … DR Falci, AA Monteiro, CF Braz Caurio, TCO Magalhães, MO Xavier, ... Open forum infectious diseases 6 (4), ofz073, 2019 | 106 | 2019 |
| Disease burden of chronic hepatitis C in Brazil PRA Ferreira, CE Brandão-Mello, C Estes, FL Gonçales, HSM Coelho, ... Brazilian Journal of Infectious Diseases 19 (4), 363-368, 2015 | 101 | 2015 |
| Tradução e validação de um questionário de avaliação de qualidade de vida em AIDS no Brasil PC De Soárez, A Castelo, P Abrão, WC Holmes, RM Ciconelli Revista panamericana de salud pública 25 (1), 69-76, 2009 | 101* | 2009 |
| Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C M Colombo, I Fernández, D Abdurakhmanov, PA Ferreira, SI Strasser, ... Gut 63 (7), 1150-1158, 2014 | 72 | 2014 |
| Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach AS Benzaken, R Girade, E Catapan, GFM Pereira, EC Almeida, ... Brazilian Journal of Infectious Diseases 23, 182-190, 2019 | 69 | 2019 |
| Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy EFR da Silva, FAH Fonseca, CN Franca, PRA Ferreira, MCO Izar, ... Aids 25 (13), 1595-1601, 2011 | 69 | 2011 |
| Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients DC de Almeida, MCP Franco, DRP Dos Santos, MC Santos, IS Maltoni, ... PLoS One 16 (5), e0251048, 2021 | 63 | 2021 |
| Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Z Temesgen, CD Burger, J Baker, C Polk, CR Libertin, CF Kelley, ... The Lancet Respiratory Medicine 10 (3), 237-246, 2022 | 61 | 2022 |
| Proceedings of the 3rd IPLeiria’s International Health Congress: Leiria, Portugal. 6-7 May 2016 CC Tomás, E Oliveira, D Sousa, M Uba-Chupel, G Furtado, C Rocha, ... BMC Health Services Research 16, 111-242, 2016 | 49* | 2016 |
| The case for simplifying and using absolute targets for viral hepatitis elimination goals Polaris Observatory Collaborators, H Razavi, S Blach, D Razavi-Shearer, ... Journal of viral hepatitis 28 (1), 12-19, 2021 | 48 | 2021 |
| Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial RS Diaz, IL Shytaj, LB Giron, B Obermaier, E della Libera Jr, J Galinskas, ... International journal of antimicrobial agents 54 (5), 592-600, 2019 | 47 | 2019 |
Simone TenoreMEDICA DA ESCOLA PAULISTA DE MEDICINA, UNIVERSIDADE FEDERAL DE SÃO PAULO E MEDICA DO CRT DST AIDS DE在 crt.saude.sp.gov.br 的电子邮件经过验证
